In people with Parkinson’s disease, sleep disturbances and excessive daytime sleepiness (EDS) were associated with the impairment of the autonomic nervous system that controls involuntary bodily functions, a study shows. Depression and rapid eye movement sleep behavior disorder (RBD), or dream-enacting behavior, also contributed to problems sleeping at night…
The first patient has been dosed in a Phase 2 trial testing BIA 28-6156, Bial’s investigational therapy for Parkinson’s disease patients with mutations in the glucocerebrosidase 1 (GBA1) gene. The ACTIVATE (NCT05819359) study is currently screening Parkinson’s patients, ages 35 to 80 years, across multiple sites in…
NurrOn Pharmaceuticals has partnered with South Korean HanAll Biopharma and Daewoong Pharmaceutical to continue developing its candidate therapy for Parkinson’s disease and other neurodegenerative disorders. A Phase 1 clinical trial of its lead oral investigational therapy ATH-399A is expected to start this year. Before testing it…
Long-term treatment with sargramostim, an immune-modulating medication from Partner Therapeutics, was safe and improved motor function for five men with Parkinson’s disease, according to data from a small open-label Phase 1 clinical trial. Evidence suggested the therapy exerted its benefits by boosting the function of anti-inflammatory…
The Michael J. Fox Foundation (MJFF) is partnering with H1 to enhance the connections between physicians, researchers and patients with Parkinson’s disease. MJFF will use H1’s Trial Landscape platform to identify and communicate with lead researchers and physicians treating Parkinson’s patients, including those in populations typically unrepresented…
A new digital tool called MAP DBS may help improve the efficiency of deep brain stimulation (DBS) for people with Parkinson’s disease, a new study suggests. “We showed that MAP DBS can improve the time spent at the initial DBS programming visit when compared to [standard-of-care] procedures, which has…
An experimental molecule called ONO-2506 was found to reduce the occurrence of abnormal movements — dyskinesia — resulting from early levodopa treatment without compromising levodopa’s therapeutic effects in a rat model of Parkinson’s disease. The mechanisms by which ONO-2506 was able to ease levodopa-induced dyskinesia (LID) appeared…
Several people with Parkinson’s disease were able to improve their ability to walk by using a “wearable cyborg” over their torso, a study reports. The study, “Gait improvement with wearable cyborg HAL trunk unit for parkinsonian patients: five case reports,” was published in Scientific Reports. The work…
A 12-week virtual music therapy program was found to reduce apathy and depression among people with Parkinson’s disease — and to help ease feelings of burden for their caregivers, a new study reported. “Group music therapy is an effective treatment for apathy in PD [Parkinson’s disease] and may improve…
At an upcoming free webinar, hosted by Synapticure, experts will discuss how the chemical trichloroethylene or TCE — a widely-used solvent now well known to have toxic side effects — may be a cause of Parkinson’s disease. The webinar, “TCE: An Invisible Cause of Parkinson’s,” is taking place via…
Get regular updates to your inbox.
